BR112013010367A2 - métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina - Google Patents
métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxinaInfo
- Publication number
- BR112013010367A2 BR112013010367A2 BR112013010367A BR112013010367A BR112013010367A2 BR 112013010367 A2 BR112013010367 A2 BR 112013010367A2 BR 112013010367 A BR112013010367 A BR 112013010367A BR 112013010367 A BR112013010367 A BR 112013010367A BR 112013010367 A2 BR112013010367 A2 BR 112013010367A2
- Authority
- BR
- Brazil
- Prior art keywords
- endotoxin
- composition
- free
- tlr4 agonist
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina. composições e métodos para evitar e/ou reduzir a deposição de amiloide em um paciente que compreende o tratamento de um paciente com uma composição que compreende um agonista de tlr4 isento de endotoxina são fornecidos. também é fornecido um agonista de tlr4 isento de endotoxina para evitar e/ou reduzir doença de alzheimer. as composições farmacêuticas consistindo de ou que consistem essencialmente de, um aminoalquil glucosaminida fosfato, 3d-mpl, as01b ou um agp em combinação com um óleo em emulsão de água também são fornecidos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40723510P | 2010-10-27 | 2010-10-27 | |
GBGB1101331.5A GB201101331D0 (en) | 2011-01-26 | 2011-01-26 | Compositions and uses |
PCT/EP2011/068909 WO2012055981A1 (en) | 2010-10-27 | 2011-10-27 | Immunogenic compositions and methods for treating neurologic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013010367A2 true BR112013010367A2 (pt) | 2016-08-02 |
Family
ID=43769635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013010367A BR112013010367A2 (pt) | 2010-10-27 | 2011-10-27 | métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130216614A1 (pt) |
EP (2) | EP2632488B1 (pt) |
JP (1) | JP6093304B2 (pt) |
CN (2) | CN103269719A (pt) |
BR (1) | BR112013010367A2 (pt) |
CA (1) | CA2815278A1 (pt) |
ES (1) | ES2627806T3 (pt) |
GB (1) | GB201101331D0 (pt) |
WO (1) | WO2012055981A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015165980A2 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
CA2946931A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
WO2015185602A1 (en) | 2014-06-04 | 2015-12-10 | Affiris Ag | Treatment and prevention of parkinson's disease (pd) |
US10006084B2 (en) | 2015-04-30 | 2018-06-26 | Sakura Finetek U.S.A., Inc. | Methods to reduce evaporation during elevated temperature |
RU2018107930A (ru) * | 2015-08-06 | 2019-09-06 | Глэксосмитклайн Байолоджикалз Са | Агонисты tlr4, их композиции и применение для лечения рака |
TW201716084A (zh) * | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
CA2983930C (en) * | 2016-04-15 | 2023-05-02 | Sakura Finetek U.S.A., Inc. | Methods to reduce evaporation during elevated temperature |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
HRP990246A2 (en) * | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
US6787637B1 (en) * | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
EP1284740B1 (en) | 2000-05-19 | 2008-05-21 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with monosaccharide-based compounds |
ES2261453T3 (es) * | 2000-08-04 | 2006-11-16 | Corixa Corporation | Nuevos compuestos inmunoefectores. |
US7030094B2 (en) * | 2002-02-04 | 2006-04-18 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21 |
EP1482955B1 (en) | 2002-02-04 | 2013-12-25 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
KR100885008B1 (ko) | 2002-02-04 | 2009-02-20 | 코릭사 코포레이션 | 신규 면역효과기 화합물 |
US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
HUE026376T2 (en) | 2003-01-06 | 2016-05-30 | Corixa Corp | Certain aminoalkyl glucosamide phosphate compounds and their use |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
WO2004087733A2 (en) | 2003-03-28 | 2004-10-14 | New York University | Prevention and treatment of alzheimer amyloid deposition |
SG149039A1 (en) * | 2003-12-17 | 2009-01-29 | Elan Pharm Inc | Ass IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
AU2008207025B2 (en) * | 2007-01-15 | 2012-08-23 | Glaxosmithkline Biologicals Sa | Vaccine |
US10383887B2 (en) | 2008-02-20 | 2019-08-20 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
CA2748038A1 (en) * | 2008-12-23 | 2010-07-01 | Glaxosmithkline Biologicals S.A. | Method for inducing a trif-bias |
-
2011
- 2011-01-26 GB GBGB1101331.5A patent/GB201101331D0/en not_active Ceased
- 2011-10-27 JP JP2013535445A patent/JP6093304B2/ja not_active Expired - Fee Related
- 2011-10-27 US US13/881,870 patent/US20130216614A1/en not_active Abandoned
- 2011-10-27 EP EP11776775.6A patent/EP2632488B1/en not_active Not-in-force
- 2011-10-27 EP EP16188862.3A patent/EP3153176A1/en not_active Withdrawn
- 2011-10-27 CA CA2815278A patent/CA2815278A1/en not_active Abandoned
- 2011-10-27 BR BR112013010367A patent/BR112013010367A2/pt not_active IP Right Cessation
- 2011-10-27 WO PCT/EP2011/068909 patent/WO2012055981A1/en active Application Filing
- 2011-10-27 CN CN2011800628443A patent/CN103269719A/zh active Pending
- 2011-10-27 CN CN201610196070.8A patent/CN105769886A/zh active Pending
- 2011-10-27 ES ES11776775.6T patent/ES2627806T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
WO2012055981A1 (en) | 2012-05-03 |
JP6093304B2 (ja) | 2017-03-08 |
ES2627806T3 (es) | 2017-07-31 |
CN103269719A (zh) | 2013-08-28 |
EP2632488A1 (en) | 2013-09-04 |
EP3153176A1 (en) | 2017-04-12 |
GB201101331D0 (en) | 2011-03-09 |
EP2632488B1 (en) | 2017-03-29 |
CN105769886A (zh) | 2016-07-20 |
JP2013540800A (ja) | 2013-11-07 |
US20130216614A1 (en) | 2013-08-22 |
CA2815278A1 (en) | 2012-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013010367A2 (pt) | métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina | |
BR112014006220A2 (pt) | composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica | |
BR112015021352A2 (pt) | composições antimicrobianas | |
BRPI1009842B8 (pt) | uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas | |
BR112015008447A2 (pt) | métodos para tratar câncer | |
BRPI0905733B8 (pt) | composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
BR112013017845A2 (pt) | agente antidiabético de abaixamento de lipídio | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
CL2009001484A1 (es) | Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia. | |
BR112015008487A2 (pt) | compostos de benzeno substituído | |
ES2721448T3 (es) | GLYX-13 para uso en el tratamiento de enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington | |
BR112014027204A2 (pt) | conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos | |
ECSP11011297A (es) | Proteinas ligadoras il-17 | |
CR20120596A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
BRPI0915536A2 (pt) | salicilatos acetilados de ácidos graxos e seus usos | |
BR112012031487A2 (pt) | processo para a produção de uma emulsão em água, emulsão de óleo em água, composição imunogênica, uso de uma emulsão de óleo em água ou da composição imunogênica,método de tratamento,e,kit | |
BR112012016570A2 (pt) | composto, composição farmacêutica, método para antagonizar a heparina não fracionada, heparina de peso molecular baixo, ou derivado de heparina /heparina de peso molecular baixo, e, uso do composto | |
BR112015019395A2 (pt) | composições e métodos para tratar e reparar tendões | |
BR112016003584A8 (pt) | composições farmaceuticas e uso das mesmas para regressão de placa acelerada | |
BR112015025787A8 (pt) | composição para o tratamento e/ou pós-tratamento do câncer e uso de uma combinação de óleo de peixe e suco na fabricação de tal composição | |
BR112013014189A2 (pt) | composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções | |
BR112014011481A2 (pt) | hidrolisado de colágeno e seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |